UA93226C2 - (4r)-1'-[(2e)-3-(3,4-dichlorophenyl)prop-2-ene-1-yl]-2h,5h-spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-trione and use thereof - Google Patents

(4r)-1'-[(2e)-3-(3,4-dichlorophenyl)prop-2-ene-1-yl]-2h,5h-spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-trione and use thereof

Info

Publication number
UA93226C2
UA93226C2 UAA200809311A UAA200809311A UA93226C2 UA 93226 C2 UA93226 C2 UA 93226C2 UA A200809311 A UAA200809311 A UA A200809311A UA A200809311 A UAA200809311 A UA A200809311A UA 93226 C2 UA93226 C2 UA 93226C2
Authority
UA
Ukraine
Prior art keywords
trione
imidazolidine
dichlorophenyl
spiro
ene
Prior art date
Application number
UAA200809311A
Other languages
English (en)
Russian (ru)
Inventor
Кармен Лунг
Мирослав Томашевски
Саймон By
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA93226(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of UA93226C2 publication Critical patent/UA93226C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
UAA200809311A 2006-02-07 2007-06-02 (4r)-1'-[(2e)-3-(3,4-dichlorophenyl)prop-2-ene-1-yl]-2h,5h-spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-trione and use thereof UA93226C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77111906P 2006-02-07 2006-02-07

Publications (1)

Publication Number Publication Date
UA93226C2 true UA93226C2 (en) 2011-01-25

Family

ID=38345567

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200809311A UA93226C2 (en) 2006-02-07 2007-06-02 (4r)-1'-[(2e)-3-(3,4-dichlorophenyl)prop-2-ene-1-yl]-2h,5h-spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-trione and use thereof

Country Status (21)

Country Link
US (2) US20070185179A1 (enExample)
EP (1) EP2013215A4 (enExample)
JP (1) JP2009526043A (enExample)
KR (1) KR20080094906A (enExample)
CN (1) CN101415711A (enExample)
AR (1) AR059265A1 (enExample)
AU (1) AU2007212786B2 (enExample)
BR (1) BRPI0707423A2 (enExample)
CA (1) CA2641632A1 (enExample)
CL (1) CL2009000523A1 (enExample)
IL (1) IL192890A0 (enExample)
NO (1) NO20083547L (enExample)
NZ (1) NZ571070A (enExample)
RU (1) RU2421457C2 (enExample)
SA (1) SA07280027B1 (enExample)
SG (1) SG169387A1 (enExample)
TW (1) TW200801011A (enExample)
UA (1) UA93226C2 (enExample)
UY (1) UY30132A1 (enExample)
WO (1) WO2007091947A2 (enExample)
ZA (1) ZA200806407B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013057944A1 (ja) * 2011-10-19 2013-04-25 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬
TWI586668B (zh) * 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CN108409746B (zh) * 2018-05-15 2021-08-24 中山大学 一种含吡咯或吲哚并氮杂环烷结构的手性氧代螺环吲哚类化合物及其消旋体和制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490381A (en) 1979-11-13 1984-12-25 Imperial Chemical Industries Plc 1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones
ZA806623B (en) * 1979-11-13 1981-12-30 Ici Ltd Substituted indoline-2-one derivatives
IE52879B1 (en) * 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
GB8331194D0 (en) 1982-12-20 1983-12-29 Ici Plc Chemical process
US4611062A (en) * 1984-03-26 1986-09-09 Imperial Chemical Industries Plc Process for resolving certain spiro compounds
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
JP2003505388A (ja) * 1999-07-21 2003-02-12 アストラゼネカ・アクチエボラーグ 新規化合物
US7248802B2 (en) 2002-11-27 2007-07-24 Nokia Corporation Distribution of a synchronization signal in an optical communication system
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
CA2526387A1 (en) 2003-06-12 2004-12-23 Astellas Pharma Inc. Benzamide derivative or salt thereof
GB0326633D0 (en) * 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
WO2006007851A2 (en) 2004-07-19 2006-01-26 Novo Nordisk A/S Capsaicin inhibitors for treating obesity and-related disorders
WO2007091948A2 (en) 2006-02-07 2007-08-16 Astrazeneca Ab Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1

Also Published As

Publication number Publication date
BRPI0707423A2 (pt) 2011-05-03
KR20080094906A (ko) 2008-10-27
RU2421457C2 (ru) 2011-06-20
US20090137650A1 (en) 2009-05-28
AR059265A1 (es) 2008-03-19
AU2007212786A8 (en) 2010-05-06
WO2007091947A3 (en) 2007-10-04
UY30132A1 (es) 2009-07-17
WO2007091947A8 (en) 2008-08-07
JP2009526043A (ja) 2009-07-16
AU2007212786A1 (en) 2007-08-16
WO2007091947A2 (en) 2007-08-16
CL2009000523A1 (es) 2009-07-17
AU2007212786B2 (en) 2011-06-02
US7868181B2 (en) 2011-01-11
CN101415711A (zh) 2009-04-22
TW200801011A (en) 2008-01-01
EP2013215A4 (en) 2010-09-08
ZA200806407B (en) 2009-04-29
CA2641632A1 (en) 2007-08-16
SG169387A1 (en) 2011-03-30
SA07280027B1 (ar) 2010-11-22
EP2013215A2 (en) 2009-01-14
NZ571070A (en) 2011-07-29
RU2008131905A (ru) 2010-03-20
IL192890A0 (en) 2009-02-11
US20070185179A1 (en) 2007-08-09
NO20083547L (no) 2008-11-05

Similar Documents

Publication Publication Date Title
MX2009004096A (es) Metabolitos de talarozol.
WO2008062905A3 (en) Heteromonocyclic compound and use thereof
TW200738672A (en) Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
WO2002062766A3 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
AU6337999A (en) Core-extended perylene bisimides
IL164511A0 (en) Heterocyclic compounds
WO2006011050A3 (en) Pyridine derivatives
WO2009027393A3 (en) Pyrazole compounds for controlling invertebrate pests
UA93043C2 (ru) ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ПОЛУЧЕНИЯ ТРАНС-5-ХЛОР-2-МЕТИЛ-2,3,3А,12В-ТЕТРАГИДРО-1Н-ДИБЕНЗ[2,3:6,7]ОКСЕПИНО[4,5-с]ПИРОЛА
EP2078721A3 (en) Thieno-pyrimidime compounds having fungicidal activity
WO2009018065A3 (en) Novel glucokinase activators and methods of using same
AU2003218110A1 (en) C3-cyano epothilone derivatives
WO2007082262A3 (en) Novel compounds
WO2006030977A3 (en) Imidazole derivatives as large conductance calcium-activated k channel openers
UA93226C2 (en) (4r)-1'-[(2e)-3-(3,4-dichlorophenyl)prop-2-ene-1-yl]-2h,5h-spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-trione and use thereof
WO2010068520A3 (en) Substituted imidazoheterocycle derivatives
WO2005077922A3 (en) Process for the preparation of substituted triazole compounds
TW200626600A (en) Octahydropyrrolo[3, 4-c]pyrrole derivatives
WO2005115984A3 (en) Large conductance calcium-activitated k channel opener
WO2006035244A3 (en) Ecteinascidin compounds as anti -inflammatory agents
CA2562251A1 (en) Pyrazolo'4,3-d pyrimidines
WO2006088903A3 (en) Pyrazole compounds
WO2006133928A3 (en) Use of phenylsemicarbazones for seed treatment
PL375213A1 (en) A process for the preparation of clopidogrel
MX2011011246A (es) Derivados de 1-h-pirazolo [4,3-c] isoquinoleinas, su preparacion y su uso en terapeutica.